Ann: Magnum Pursues Main Board Listing with Critical Appointment, page-27

First 27 Last

Share
Profile

Follow
Newby1

575 Posts.

130

20/01/24

14:11

Post #: 71977662
Share

Originally posted by ASXMGU: ↑

This was my comment....

"Quite possible. When EG & S, were appointed in Aug 23, it was for CR etc and penny listing on the OTC - QB. However that now seems to have changed with the Company deciding to terminate the OTC - QB listing process.
EAS had been appointed by Magnum as its 'Corporate Strategist' to inform and shape the financing strategy for accessing all US Capital Markets. Now it seems, EAS will pursue a strategy of listing on a 'Major' US Stock Exchange, rather than the OTC - QB. EG & S will provide the legal oversight to support and facilitate that activity".
-------------------------------The OTCQB functions as follows. (as you pointed out, you said you knew this) The OTCQB market is the second tier of the markets operated by OTC Markets Group, below OTCQX and above Pink. Unlike the OTCQX market, there are no minimum financial standards on the OTCQB market other than a US$0.01 minimum bid price (penny listing) and the requirement that companies may not be in bankruptcy.

The phrase "penny listing" wasn't mentioned in the Aug release, I added that in my above comment, to reply to GoldStar, as I know how the OTC functions.. If you look at the screenshot below, you will see the mention of the OTC termination.

You don't need to apologise, you just read to far into my comment.

Expand

I see the mention of otc termination my point is they never mentioned anything about listing on the otc.
deceitful at best.
not getting into an argument with someone who talks down to shareholders like you have. All the best

MGU Price at posting: 2.6¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 57 more messages in this thread...

First 27 Last

Add MGU (ASX) to my watchlist

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $8.902M

Open	High	Low	Value	Volume
1.1¢	1.1¢	1.1¢	$5.958K	541.5K

Buyers (Bids)

No.	Vol.	Price($)
4	184567	1.1¢

Sellers (Offers)

Price($)	Vol.	No.
1.2¢	183210	2

View Market Depth

No.	Vol.	Price($)
4	184567	0.011
11	1691778	0.010
6	1603311	0.009
6	1041300	0.008
2	311111	0.007

Price($)	Vol.	No.
0.012	183210	2
0.013	151423	1
0.014	1140071	5
0.015	1141323	4
0.016	67241	1

Last trade - 15.01pm 07/10/2024 (20 minute delay)

MGU (ASX) Chart

Ann: Magnum Pursues Main Board Listing with Critical Appointment, page-27

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Magnum Pursues Main Board Listing with Critical Appointment, page-27

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News